All Stories

  1. 68Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma
  2. Tumor targeting and imaging with dual-peptide conjugated multifunctional liposomal nanoparticles
  3. A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma
  4. 68Ga-Triacetylfusarinine C and 68Ga-Ferrioxamine E for Aspergillus Infection Imaging: Uptake Specificity in Various Microorganisms
  5. 68Ga-DOTA0-Tyr3-octreotide positron emission tomography in head and neck squamous cell carcinoma
  6. [68Ga]NS3-RGD and [68Ga] Oxo-DO3A-RGD for imaging αvβ3 integrin expression: synthesis, evaluation, and comparison
  7. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide
  8. Influence of PEGylation and RGD loading on the targeting properties of radiolabeled liposomal nanoparticles
  9. Microbial challenge tests on nonradioactive TiO2-based 68Ge/68Ga generator columns
  10. Gallium-68 – A New Opportunity For PET Available From a Long Shelflife Generator – Automation and Applications
  11. Preclinical evaluation of two 68Ga-siderophores as potential radiopharmaceuticals for Aspergillus fumigatus infection imaging
  12. Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours
  13. In vitro and in vivo evaluation of selected 68Ga-siderophores for infection imaging
  14. Feasibility and availability of 68Ga-labelled peptides
  15. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine: a clarification
  16. Targeting properties of peptide-modified radiolabeled liposomal nanoparticles
  17. [ 99m Tc]Demotensin VI: Biodistribution and Initial Clinical Results in Tumor Patients of a Pilot/Phase I Study
  18. Radiolabelling of peptides for PET, SPECT and therapeutic applications using a fully automated disposable cassette system
  19. Preclinical Evaluation of Radiolabeled DOTA-Derivatized Cyclic Minigastrin Analogs for Targeting Cholecystokinin Receptor Expressing Malignancies
  20. Radiopharmacy: regulations and legislations in relation to human applications
  21. Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607
  22. [68Ga]NODAGA-RGD for imaging αvβ3 integrin expression
  23. Influence of biological assay conditions on stability assessment of radiometal-labelled peptides exemplified using a 177Lu-DOTA-minigastrin derivative
  24. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine
  25. Radiotracer II: Peptide-Based Radiopharmaceuticals
  26. Novel 99mTc ‘4 + 1’ peptide conjugates: Tuning the biodistribution by variation of coligands
  27. Comparison of 68Ga-siderophores for imaging Aspergillus fumigatus infections with PET
  28. Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals
  29. Impurity in 68Ga-Peptide Preparation Using Processed Generator Eluate
  30. Full automation of 68Ga labelling of DOTA-peptides including cation exchange prepurification
  31. Radiolabeling of lipid-based nanoparticles for diagnostics and therapeutic applications: a comparison using different radiometals
  32. Preclinical Evaluation of In-111 and Ga-68 Labelled Minigastrin Analogues for CCK-2 Receptor Imaging
  33. Role of radiopharmaceuticals in the diagnosis and treatment of neuroendocrine tumours
  34. Cyclic Minigastrin Analogues for Gastrin Receptor Scintigraphy with Technetium-99m: Preclinical Evaluation
  35. Practical and general method for the direct synthesis of alkyl fluorides from alcohols under mild conditions: a reinvestigation
  36. 68Ga- and 111In-labelled DOTA-RGD peptides for imaging of αvβ3 integrin expression
  37. A fully automated synthesis for the preparation of 68Ga-labelled peptides
  38. Therapy of differentiated thyroid cancer
  39. In Vitro and In Vivo Evaluation of a Novel 99mTc(CO)3-Pyrazolyl Conjugate of cyclo-(Arg-Gly-Asp-d-Tyr-Lys)
  40. Evidence for Somatostatin receptor 2 in thyroid tissue
  41. [99mTc]HYNIC-RGD for imaging integrin αvβ3 expression
  42. Comparison of different methods for radiochemical purity testing of [99mTc-EDDA-HYNIC-D-Phe1,Tyr3]-Octreotide
  43. Image fusion analysis of 99mTc-HYNIC-Tyr3-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours
  44. Nuclear medicine in the detection and management of pancreatic islet-cell tumours
  45. Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats
  46. Radiopharmaceutical development of a freeze-dried kit formulation for the preparation of [99mTc-EDDA-HYNIC-D-Phe1, Tyr3]-octreotide, a somatostatin analog for tumor diagnosis
  47. 99m Tc-EDDA/HYNIC-TOC scintigraphy in oncological diagnostics: methodological considerations
  48. 99m Tc-N 4 -[Tyr 3 ]Octreotate Versus 99m Tc-EDDA/HYNIC-[Tyr 3 ]Octreotide: An Intrapatient Comparison of Two Novel Technetium-99m Labeled Tracers for Somatostatin Receptor Scintigraphy
  49. Analysis of accumulation of 99mTc-octreotide and 99mTc-EDDA/HYNIC-Tyr3-octreotide in the rat kidneys
  50. 99mTc-EDDA/HYNIC-TOC and 18F-FDG in thyroid cancer patients with negative 131I whole-body scans
  51. Peptide Targeted Imaging of Cancer
  52. 99mTc-Demotate 1: first data in tumour patients?results of a pilot/phase I study
  53. Image fusion analysis of 99m Tc-HYNIC-octreotide scintigraphy and CT/MRI in patients with thyroid-associated orbitopathy: the importance of the lacrimal gland
  54. Preparation via coligand exchange and characterization of [99mTc‐EDDA‐HYNIC‐D‐Phe1,Tyr3]Octreotide (99mTc–EDDA/HYNIC–TOC)
  55. Evaluation of Striatal Dopamine Transporter Function in Rats by in Vivo β-[123I]CIT Pinhole SPECT
  56. Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in Graves’ disease
  57. Erythroid 5‐aminolevulinate synthase, ferrochelatase and DMT1 expression in erythroid progenitors: differential pathways for erythropoietin and iron‐dependent regulation
  58. Authors’ reply to letter to the editor by G. Calmanovici
  59. Methodological considerations influence the clinical value of parathyroid localisation diagnostics
  60. Surfactant protein B labelled with [99mTc(CO)3(H2O)3]+ retains biological activity in vitro
  61. 53. Rhenium-188 labelling of HYNIC-octreotide analogues
  62. 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours: first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives
  63. Human pharmacokinetics of a new 99mTc labelled somatostatin anlogue in comparison with 111In-labelled derivatives
  64. 11. First clinical assessment of a new Tc-99m-labelled somatostatin analogue
  65. 17. Pre-clinical development of a superior Tc-99m-labelled somatostatin analogue
  66. Radiochemical purity of routinely prepared 99Tcm radiopharmaceuticals: A retrospective study
  67. Technetium-99m somatostatin analogues: effect of labelling methods and peptide sequence
  68. Preparation, 99mTc-Labeling, and in Vitro Characterization of Hynic and N3S Modified RC-160 and [TYR3]octreotide
  69. 99m-Technetium-labelled peptide-HYNIC conjugates: effects of lipophilicity and stability on biodistribution
  70. Preparation, 99mTc-Labeling, and in Vitro Characterization of HYNIC and N3S Modified RC-160 and [Tyr3]Octreotide
  71. Myocardial fatty acid metabolism during acute cardiac allograft rejection
  72. The use of electronic autoradiography in radiopharmacy
  73. Brain perfusion scintigraphy with 99m Tc-HMPAO or 99m Tc-ECD and 123 I-β-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease
  74. Brain perfusion scintigraphy with99mTc-HMPAO or99mTc-ECD and123I-β-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease
  75. Evaluation of Immunological Mechanisms Mediating Thyroid-Associated Ophthalmopathy by Radionuclide Imaging Using the Somatostatin Analog 111 In-Octreotide
  76. Training in Radiopharmaceutical Quality Control
  77. Bone scintigraphy versus human immunoglobulin scintigraphy in the clinical investigation of psoriatic arthropathy
  78. Technetium-99m human immunoglobulin scintigraphy in psoriatic arthropathy: first results
  79. Technetium-99m human immunoglobulin scintigraphy in psoriatic arthropathy: first results
  80. Failure of labelling of anti-granulocyte antibody
  81. A simple two-strip method to determine the radiochemical purity of technetium-99m mercaptoacetyltriglycine
  82. Quality Control Methods of 99mTc Pharmaceuticals